
- CIN
- U60100MH2019PLC323444
- ISIN
- INE0DJ201029
- Incorporated
- 31 Mar 2019
- Registered state
- Maharashtra
Key valuation
- Market cap
- ₹9,538 Cr
- P/E
- —
- Debt / equity
- 0.6x
- Shares outstanding
- 17,03,21,42,857
Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.
Price history
Dated dealer-quote averages, plotted on a true time scale. There is no continuous trading behind these numbers.
About Pharmeasy
API Holdings Limited is the parent company of PharmEasy, one of India's largest online pharmacy and healthcare platforms. It was incorporated in 2019 and is based in Mumbai.
Through about 26 subsidiaries, the group runs consumer medicine delivery, pharmaceutical distribution to retailers, diagnostics and teleconsultation. Customers order prescription medicines, OTC and wellness products on PharmEasy, while subsidiaries such as Thyrocare provide diagnostic testing. Much of the group's growth came through acquisitions, including Thyrocare and Docon.
API Holdings remains loss-making but is narrowing its losses: it reported revenue of ₹5,872 crore and a net loss of ₹1,572 crore in FY2025, compared with ₹5,664 crore and a ₹2,534 crore loss in FY2024.
Key highlights
- Incorporated in 2019
Financial snapshot
FY2025
- Revenue FY2025
- ₹5,872.16 Cr
- EBITDA
- ₹-841.80 Cr
- PAT
- ₹-1,572.39 Cr
- Net worth
- ₹3,272.28 Cr
- Total debt
- ₹2,034.00 Cr
- Cash & equivalents
- ₹118.99 Cr
- Operating cash flow
- ₹-223.53 Cr
- EPS
- ₹-0.92
Management & board
- APSince 2021
Aditya Puri
Director
- RRSince 2026
Ravi Rajagopal
Additional Director
- DCSince 2021
Deepak Calian Vaidya
Director
- AKSince 2025
Alok Kumar Jagnani
CFO, Whole-time director
- RRSince 2024
Ranjan Ramdas Pai
Director
- SSSince 2021
Subramaniam Somasundaram
Director
- SPSince 2024
Shyam Powar
Director
- JDSince 2021
Jaydeep Dahyalal Tank
Director
- SBSince 2020
Siddharth Bhaskar Shah
Director
- VRSince 2021
Vineeta Rai
Director
- ASSince 2021
Ashutosh Sharma
Director
- NRSince 2019
Namita Rungta
Individual Promoter
- NRSince 2019
Nimesh Rungta
Individual Promoter
- RFSince 2025
Rahul Franklin Guha
CEO, Managing Director
Reported financials · FY2021–FY2025
Figures in ₹ crore unless stated.
| Particulars | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY | CAGR |
|---|---|---|---|---|---|---|---|
| Profit & loss | |||||||
| Revenue from operationsYoY +3.7%CAGR +25.9% | 2,335 | 5,729 | 6,644 | 5,664 | 5,872 | +3.7% | +25.9% |
| Other incomeYoY +13.9%CAGR +43.6% | 25 | 52 | 56 | 95 | 108 | +13.9% | +43.6% |
| Total expensesYoY -0.6%CAGR +25.5% | 2,905 | 8,492 | 8,974 | 7,255 | 7,209 | -0.6% | +25.5% |
| EBITDA | -569 | -2,294 | -4,288 | -1,578 | -842 | — | — |
| Depreciation & amortisationYoY -21.8%CAGR +50.5% | 33 | 159 | 243 | 216 | 169 | -21.8% | +50.5% |
| EBIT | -602 | -2,452 | -4,531 | -1,794 | -1,011 | — | — |
| Finance costYoY -30.5%CAGR +84.8% | 43 | 258 | 666 | 728 | 506 | -30.5% | +84.8% |
| Profit before tax | -620 | -3,971 | -5,197 | -2,522 | -1,517 | — | — |
| Tax expenseYoY +382.6%CAGR +27.4% | 21 | 22 | 15 | 12 | 56 | +382.6% | +27.4% |
| Profit after tax | -641 | -3,993 | -5,212 | -2,534 | -1,572 | — | — |
| Earnings per share | ₹-0.38 | ₹-2.34 | ₹-3.06 | ₹-1.49 | ₹-0.92 | — | — |
| Balance sheet | |||||||
| Net worthYoY +26.4%CAGR -2.2% | 3,581 | 7,022 | 2,437 | 2,588 | 3,272 | +26.4% | -2.2% |
| Total debtYoY -50.4%CAGR +342.4% | 5 | 2,585 | 4,120 | 4,098 | 2,034 | -50.4% | +342.4% |
| Current liabilitiesYoY -49.1%CAGR +100.1% | 111 | 3,762 | 2,323 | 3,502 | 1,781 | -49.1% | +100.1% |
| Cash & equivalentsYoY -63.7%CAGR -15.2% | 230 | 157 | 194 | 328 | 119 | -63.7% | -15.2% |
| Current assetsYoY -27.7%CAGR +9.7% | 1,736 | 2,502 | 2,535 | 3,476 | 2,513 | -27.7% | +9.7% |
| Total assetsYoY -16.8%CAGR +9.2% | 4,905 | 11,398 | 8,256 | 8,390 | 6,977 | -16.8% | +9.2% |
| Cash flow | |||||||
| Operating activities | -179 | -2,589 | -744 | -61 | -224 | — | — |
| Investing activities | -954 | -5,789 | -72 | -1,261 | 775 | — | — |
| Financing activitiesYoY -152.2%CAGR — | 1,119 | 8,305 | 853 | 1,457 | -760 | -152.2% | — |
| Free cash flow | -184 | 2,446 | -839 | -133 | -304 | — | — |
| Net change in cashYoY -254.7%CAGR — | -15 | -73 | 37 | 135 | -208 | -254.7% | — |
YoY compares the latest year with the one before it. CAGR runs from the oldest reported year to the latest. A dash means the year is missing, or the starting figure is zero or negative, so a percentage would mislead.
Margins, returns, liquidity, leverage and every other ratio from these figures: see RatiosRevenue, EBITDA and PAT
₹ crore. A year with no reported figure is left out rather than drawn as zero.
- Revenue
- EBITDA
- PAT
Every ratio here is worked out from the reported figures in the Financials tab, and valuation multiples from the indicative price in the header. Nothing is a stored value. A ratio the filings cannot support (a line not reported, or a zero or negative base) is left out or shown as —, never as a misleading number. Balance-sheet ratios use year-end figures.
Valuation multiples
What the indicative price pays for the latest year's earnings, book and cash. On FY2025 figures and the ₹5.60 indicative price.
- Market cap
- ₹9,538 Cr
- Enterprise value
- ₹11,453 Cr
- Price / book (P/B)
- 2.91x
- Price / sales (P/S)
- 1.62x
- EV / sales
- 1.95x
- Earnings yield
- -16.5%
- Free cash flow yield
- -3.2%
- Cash / market cap
- 1.3%
How these are worked out
- Market cap
- Indicative price × shares outstanding
- Enterprise value
- Market cap + debt − cash
- Price / book (P/B)
- Market cap ÷ net worth
- Price / sales (P/S)
- Market cap ÷ revenue from operations
- EV / sales
- Enterprise value ÷ revenue from operations
- Earnings yield
- PAT ÷ market cap
- Free cash flow yield
- (Operating cash flow − capex) ÷ market cap
- Cash / market cap
- Cash & equivalents ÷ market cap
IPO / listing status
The company has not announced IPO details such as a DRHP filing, an expected window or its bankers. This section will update once it does.
Research & news
Research, articles and news on Pharmeasy, newest first. Open any item to read it.
Documents
Private documents are shown locked and are released to verified clients on request.
| Document | Type | FY / date | Access |
|---|---|---|---|
| Annual Report FY 2025-26Annual report · FY 2025-26 · 4.2 MB4.2 MB | Annual report | FY 2025-26 | ViewDownload |
| Annual Report FY 2023-24Annual report · FY 2023-24 · 2.4 MB2.4 MB | Annual report | FY 2023-24 | ViewDownload |
| Annual Report FY 2022-23Annual report · FY 2022-23 · 1.1 MB1.1 MB | Annual report | FY 2022-23 | ViewDownload |
Pharmeasy unlisted shares: FAQs
What is the Pharmeasy unlisted share price today?
The indicative price of API Holdings Ltd - Pharmeasy shares is ₹5.60 per share, as of 17 Nov 2026. Unlisted shares have no exchange price: this figure reflects recent off-market deals and can differ from the price on a particular trade. The price history on this page shows how it has moved.
How can I buy Pharmeasy unlisted shares?
Raise a buy enquiry on this page with the number of shares you want. Our desk confirms availability and the price, you pay from a bank account in your own name, and the shares are transferred to your demat account. You need a PAN and a demat account with any depository participant.
How can I sell Pharmeasy shares?
Raise a sell enquiry with the number of shares you hold in demat. Once the price is agreed, you transfer the shares from your demat account and the money is paid to a bank account in your name.
Is Pharmeasy planning an IPO?
API Holdings Ltd - Pharmeasy is currently at the "Pre-IPO" stage. No IPO date has been announced. A listing depends on the company and on regulatory approval.
What are Pharmeasy's revenue and profit?
In FY25, API Holdings Ltd - Pharmeasy reported revenue of ₹5,872 Cr and a loss of ₹1,572 Cr, with a net worth of ₹3,272 Cr. The Financials section has the full statements for every year we hold.
Is it legal to buy unlisted shares in India?
Yes. Shares of unlisted public companies can be bought and sold off-market and transferred between demat accounts. They carry more risk than listed shares: prices are not set on an exchange, it can take time to find a buyer, and a listing is never guaranteed.
Is there a lock-in on Pharmeasy shares after the IPO?
SEBI rules lock in shares held before an IPO for a period after listing, currently six months from allotment for most investors in a mainboard IPO. Shares bought now in the unlisted market would usually be covered by this lock-in.
How are gains on Pharmeasy unlisted shares taxed?
Gains on unlisted shares held for more than 24 months are long-term capital gains; held for less, they are short-term and taxed at your slab rate. Check the current rates with a tax adviser before you sell.

